Stocks Down Under Videos

Get a 3-month FREE TRIAL to CONCIERGE now!

Concierge gives you timely BUY and SELL alerts on ASX-listed stocks

Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals

June 5, 2024

Chimeric Therapeutics, CHM


Chimeric Therapeutics (ASX:CHM)

We spoke to Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics (ASX: CHM), about the three exciting programmes in CAR-T and NK cells, and the favourable clinical data that has been gathered in a range of cancers.

Chimeric’s share price is down a long way since the 2021 IPO, but the prospects for good licensing deals going forward is strong.


What are the Best ASX Life Sciences Stocks to invest in right now?

Check our ASX buy/sell tips